Back To Index << Back To Terminology

# Value Set eHDSIActiveIngredient 2026‑02‑06 15:15:00

This terminology is a snapshot as of 2026‑02‑11 10:48:51. Terminologies may evolve over time. If you need recent (dynamic) versions of this terminology, please retrieve it from the source.
Id | 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 | Effective Date | 2026‑02‑06 15:15:00 Other versions this id: eHDSIActiveIngredient202502 - as of 2025‑02‑17 15:15:00 eHDSIActiveIngredient202401 - as of 2024‑01‑25 16:10:00 eHDSIActiveIngredient202301 - as of 2023‑01‑17 16:05:00 eHDSIActiveIngredient202201 - as of 2022‑01‑31 16:00:00 eHDSIActiveIngredient202104 - as of 2021‑04‑19 15:45:00 eHDSIActiveIngredient202006 - as of 2020‑06‑17 11:51:00 eHDSIActiveIngredient202004 - as of 2020‑04‑23 15:10:00 epSOSActiveIngredient201912 - as of 2019‑12‑23 16:20:21 epSOSActiveIngredient201711 - as of 2017‑11‑07 14:06:21 epSOSActiveIngredientJanuary 2010 - as of 2013‑06‑03
Status | Final | Version Label | 202602
Name | eHDSIActiveIngredient | Display Name | eHDSIActiveIngredient
Usage: 70
Id | Name | Type
--- | --- | ---
Dataset
epsos-dataelement-104 | Active ingredient code | DYNAMIC
epsos-dataelement-159 | Active ingredient code | DYNAMIC
Template
1.3.6.1.4.1.12559.11.10.1.3.1.3.17 | eHDSI Allergies And Intolerances | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.17 | eHDSI Allergies And Intolerances | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.17 | eHDSI Allergies And Intolerances | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.17 | eHDSI Allergies And Intolerances | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.30 | eHDSI eP/eD Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.32 | eHDSI PS Manufactured Material | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.37 | eHDSI ingredient | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.37 | eHDSI ingredient | DYNAMIC
1.3.6.1.4.1.12559.11.10.1.3.1.3.37 | eHDSI ingredient | DYNAMIC
1.3.6.1.4.1.19376.1.5.3.1.4.6 | eHDSI Allergies And Intolerances | DYNAMIC
1.3.6.1.4.1.19376.1.5.3.1.4.6 | Allergies And Intolerances | DYNAMIC
1.3.6.1.4.1.19376.1.5.3.1.4.6 | Allergies And Intolerances | DYNAMIC
epsos-template-143 | eHDSI Material | DYNAMIC
epsos-template-143 | eHDSI Material | DYNAMIC
epsos-template-143 | eHDSI Material | DYNAMIC
epsos-template-143 | eHDSI Material | DYNAMIC
epsos-template-143 | eHDSI Material | DYNAMIC
epsos-template-143 | eHDSI Material | DYNAMIC
epsos-template-143 | eHDSI Material | DYNAMIC
epsos-template-143 | eHDSI Material | DYNAMIC
epsos-template-143 | epSOS CDA Material | DYNAMIC
epsos-template-143 | epSOS CDA Material | DYNAMIC
epsos-template-143 | epSOS CDA Material | DYNAMIC
epsos-template-143 | epSOS CDA Material | DYNAMIC
epsos-template-143 | epSOS CDA Material | DYNAMIC
epsos-template-143 | epSOS CDA Material | DYNAMIC
epsos-template-143 | epSOS CDA Material | DYNAMIC
epsos-template-143 | epSOS CDA Material | DYNAMIC
Source Code System | 2.16.840.1.113883.6.73 - WHO Anatomical Therapeutic Chemical classification - FHIR: http://www.whocc.no/atc - HL7 V2: WC
Level/ Type | Code | Display Name | Code System
--- | --- | --- | ---
0‑L | A | ALIMENTARY TRACT AND METABOLISM | WHO Anatomical Therapeutic Chemical classification
0‑L | A01 | STOMATOLOGICAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification
0‑L | A01A | STOMATOLOGICAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA | Caries prophylactic agents | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA01 | sodium fluoride | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA02 | sodium monofluorophosphate | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA03 | olaflur | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA04 | stannous fluoride | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA30 | combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA51 | sodium fluoride, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB | Antiinfectives and antiseptics for local oral treatment | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB02 | hydrogen peroxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB03 | chlorhexidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB04 | amphotericin B | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB05 | polynoxylin | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB06 | domiphen | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB07 | oxyquinoline | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB08 | neomycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB09 | miconazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB10 | natamycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB11 | various | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB12 | hexetidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB13 | tetracycline | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB14 | benzoxonium chloride | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB15 | tibezonium iodide | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB16 | mepartricin | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB17 | metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB18 | clotrimazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB19 | sodium perborate | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB21 | chlortetracycline | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB22 | doxycycline | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB23 | minocycline | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB24 | octenidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB25 | oxytetracycline | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB53 | chlorhexidine and cetylpyridinium | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC | Corticosteroids for local oral treatment | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC01 | triamcinolone | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC02 | dexamethasone | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC03 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC04 | prednisolone | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC54 | prednisolone, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD | Other agents for local oral treatment | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD01 | epinephrine | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD02 | benzydamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD05 | acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD06 | adrenalone | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD07 | amlexanox | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD08 | becaplermin | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD11 | various | WHO Anatomical Therapeutic Chemical classification
0‑L | A02 | DRUGS FOR ACID RELATED DISORDERS | WHO Anatomical Therapeutic Chemical classification
0‑L | A02A | ANTACIDS | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA | Magnesium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA01 | magnesium carbonate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA02 | magnesium oxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA03 | magnesium peroxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA04 | magnesium hydroxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA05 | magnesium silicate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA10 | combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB | Aluminium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB01 | aluminium hydroxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB02 | algeldrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB03 | aluminium phosphate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB04 | dihydroxialumini sodium carbonate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB05 | aluminium acetoacetate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB06 | aloglutamol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB07 | aluminium glycinate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB10 | combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AC | Calcium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AC01 | calcium carbonate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AC02 | calcium silicate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AC10 | combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD | Combinations and complexes of aluminium, calcium and magnesium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD01 | ordinary salt combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD02 | magaldrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD03 | almagate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD04 | hydrotalcite | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD05 | almasilate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AF | Antacids with antiflatulents | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AF01 | magaldrate and antiflatulents | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AF02 | ordinary salt combinations and antiflatulents | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AG | Antacids with antispasmodics | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AH | Antacids with sodium bicarbonate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AX | Antacids, other combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02B | DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA | H2-receptor antagonists | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA01 | cimetidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA02 | ranitidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA03 | famotidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA04 | nizatidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA05 | niperotidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA06 | roxatidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA07 | ranitidine bismuth citrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA08 | lafutidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA51 | cimetidine, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA53 | famotidine, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BB | Prostaglandins | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BB01 | misoprostol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BB02 | enprostil | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC | Proton pump inhibitors | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC01 | omeprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC02 | pantoprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC03 | lansoprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC04 | rabeprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC05 | esomeprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC06 | dexlansoprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC07 | dexrabeprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC08 | vonoprazan | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC09 | tegoprazan | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC10 | fexuprazan | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC11 | ilaprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC12 | zastaprazan | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC51 | omeprazole, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC53 | lansoprazole, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC54 | rabeprazole, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD | Combinations for eradication of Helicobacter pylori | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD01 | omeprazole, amoxicillin and metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD02 | lansoprazole, tetracycline and metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD03 | lansoprazole, amoxicillin and metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD04 | pantoprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD05 | omeprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD06 | esomeprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD07 | lansoprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD08 | bismuth subcitrate, tetracycline and metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD09 | lansoprazole, clarithromycin and tinidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD10 | lansoprazole, amoxicillin and levofloxacin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD11 | pantoprazole, amoxicillin, clarithromycin and metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD12 | rabeprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD13 | rabeprazole, amoxicillin and metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD14 | vonoprazan, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD15 | vonoprazan, amoxicillin and metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD16 | omeprazole, amoxicillin and rifabutin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD17 | vonoprazan and amoxicillin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX | Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX01 | carbenoxolone | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX02 | sucralfate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX03 | pirenzepine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX04 | methiosulfonium chloride | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX05 | bismuth subcitrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX06 | proglumide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX07 | gefarnate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX08 | sulglicotide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX09 | acetoxolone | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX10 | zolimidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX11 | troxipide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX12 | bismuth subnitrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX13 | alginic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX14 | rebamipide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX15 | teprenone | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX16 | irsogladine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX51 | carbenoxolone, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX71 | carbenoxolone, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX77 | gefarnate, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A02X | OTHER DRUGS FOR ACID RELATED DISORDERS | WHO Anatomical Therapeutic Chemical classification
0‑L | A03 | DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS | WHO Anatomical Therapeutic Chemical classification
0‑L | A03A | DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA | Synthetic anticholinergics, esters with tertiary amino group | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA01 | oxyphencyclimine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA03 | camylofin | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA04 | mebeverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA05 | trimebutine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA06 | rociverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA07 | dicycloverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA08 | dihexyverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA09 | difemerine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA30 | piperidolate | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB | Synthetic anticholinergics, quaternary ammonium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB01 | benzilone | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB02 | glycopyrronium bromide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB03 | oxyphenonium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB04 | penthienate | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB05 | propantheline | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB06 | otilonium bromide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB07 | methantheline | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB08 | tridihexethyl | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB09 | isopropamide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB10 | hexocyclium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB11 | poldine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB12 | mepenzolate | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB13 | bevonium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB14 | pipenzolate | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB15 | diphemanil | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB16 | (2-benzhydryloxyethyl)diethyl-methylammonium iodide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB17 | tiemonium iodide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB18 | prifinium bromide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB19 | timepidium bromide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB21 | fenpiverinium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB53 | oxyphenonium, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AC | Synthetic antispasmodics, amides with tertiary amines | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AC02 | dimethylaminopropionylphenothiazine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AC04 | nicofetamide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AC05 | tiropramide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AD | Papaverine and derivatives | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AD01 | papaverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AD02 | drotaverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AD30 | moxaverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AE | Serotonin receptor antagonists | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AE01 | alosetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AE03 | cilansetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX | Other drugs for functional gastrointestinal disorders | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX01 | fenpiprane | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX02 | diisopromine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX03 | chlorbenzoxamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX04 | pinaverium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX05 | fenoverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX06 | idanpramine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX07 | proxazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX08 | alverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX09 | trepibutone | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX10 | isometheptene | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX11 | caroverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX12 | phloroglucinol | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX13 | silicones | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX14 | valethamate | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX15 | menthae piperitae aetheroleum | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX30 | trimethyldiphenylpropylamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX58 | alverine, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A03B | BELLADONNA AND DERIVATIVES, PLAIN | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BA | Belladonna alkaloids, tertiary amines | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BA01 | atropine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BA03 | hyoscyamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BA04 | belladonna total alkaloids | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB | Belladonna alkaloids, semisynthetic, quaternary ammonium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB01 | butylscopolamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB02 | methylatropine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB03 | methylscopolamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB04 | fentonium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB05 | cimetropium bromide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB06 | homatropine methylbromide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03C | ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA | Synthetic anticholinergic agents in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA01 | isopropamide and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA02 | clidinium and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA03 | oxyphencyclimine and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA04 | otilonium bromide and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA05 | glycopyrronium bromide and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA06 | bevonium and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA07 | ambutonium and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA08 | diphemanil and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA09 | pipenzolate and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA30 | emepronium and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA34 | propantheline and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB | Belladonna and derivatives in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB01 | methylscopolamine and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB02 | belladonna total alkaloids and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB03 | atropine and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB04 | homatropine methylbromide and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB31 | hyoscyamine and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CC | Other antispasmodics in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03D | ANTISPASMODICS IN COMBINATION WITH ANALGESICS | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA | Synthetic anticholinergic agents in combination with analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA01 | tropenzilone and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA02 | pitofenone and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA03 | bevonium and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA04 | ciclonium and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA05 | camylofin and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA06 | trospium and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA07 | tiemonium iodide and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DB | Belladonna and derivatives in combination with analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DB04 | butylscopolamine and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DC | Other antispasmodics in combination with analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03E | ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS | WHO Anatomical Therapeutic Chemical classification
0‑L | A03EA | Antispasmodics, psycholeptics and analgesics in combination | WHO Anatomical Therapeutic Chemical classification
0‑L | A03ED | Antispasmodics in combination with other drugs | WHO Anatomical Therapeutic Chemical classification
0‑L | A03F | PROPULSIVES | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA | Propulsives | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA01 | metoclopramide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA02 | cisapride | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA03 | domperidone | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA04 | bromopride | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA05 | alizapride | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA06 | clebopride | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA07 | itopride | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA08 | cinitapride | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA09 | mosapride | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA10 | acotiamide | WHO Anatomical Therapeutic Chemical classification
0‑L | A04 | ANTIEMETICS AND ANTINAUSEANTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A04A | ANTIEMETICS AND ANTINAUSEANTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA | Serotonin (5HT3) antagonists | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA01 | ondansetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA02 | granisetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA03 | tropisetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA04 | dolasetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA05 | palonosetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA55 | palonosetron, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD | Other antiemetics | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD01 | scopolamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD02 | cerium oxalate | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD04 | chlorobutanol | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD05 | metopimazine | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD10 | dronabinol | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD11 | nabilone | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD12 | aprepitant | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD13 | casopitant | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD14 | rolapitant | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD51 | scopolamine, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD54 | chlorobutanol, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A05 | BILE AND LIVER THERAPY | WHO Anatomical Therapeutic Chemical classification
0‑L | A05A | BILE THERAPY | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA | Bile acids and derivatives | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA01 | chenodeoxycholic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA02 | ursodeoxycholic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA03 | cholic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA04 | obeticholic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA05 | ursodoxicoltaurine | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA06 | norucholic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AB | Preparations for biliary tract therapy | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AB01 | nicotinyl methylamide | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX | Other drugs for bile therapy | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX01 | piprozolin | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX02 | hymecromone | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX03 | cyclobutyrol | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX04 | maralixibat chloride | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX05 | odevixibat | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX06 | elafibranor | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX07 | seladelpar | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX08 | linerixibat | WHO Anatomical Therapeutic Chemical classification
0‑L | A05B | LIVER THERAPY, LIPOTROPICS | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA | Liver therapy | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA01 | arginine glutamate | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA03 | silymarin | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA04 | citiolone | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA05 | epomediol | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA06 | ornithine oxoglurate | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA07 | tidiacic arginine | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA08 | glycyrrhizic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA09 | metadoxine | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA10 | phospholipids | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA11 | resmetirom | WHO Anatomical Therapeutic Chemical classification
0‑L | A05C | DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION | WHO Anatomical Therapeutic Chemical classification
0‑L | A06 | DRUGS FOR CONSTIPATION | WHO Anatomical Therapeutic Chemical classification
0‑L | A06A | DRUGS FOR CONSTIPATION | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AA | Softeners, emollients | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AA01 | liquid paraffin | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AA02 | docusate sodium | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AA51 | liquid paraffin, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB | Contact laxatives | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB01 | oxyphenisatine | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB02 | bisacodyl | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB03 | dantron | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB04 | phenolphthalein | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB05 | castor oil | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB06 | senna glycosides | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB07 | cascara | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB08 | sodium picosulfate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB09 | bisoxatin | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB20 | contact laxatives in combination | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB30 | contact laxatives in combination with belladonna alkaloids | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB52 | bisacodyl, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB53 | dantron, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB56 | senna glycosides, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB57 | cascara, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB58 | sodium picosulfate, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC | Bulk-forming laxatives | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC01 | ispaghula (psylla seeds) | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC02 | ethulose | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC03 | sterculia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC05 | linseed | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC06 | methylcellulose | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC07 | triticum (wheat fibre) | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC08 | polycarbophil calcium | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC51 | ispaghula, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC53 | sterculia, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC55 | linseed, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD | Osmotically acting laxatives | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD01 | magnesium carbonate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD02 | magnesium oxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD03 | magnesium peroxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD04 | magnesium sulfate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD10 | mineral salts in combination | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD11 | lactulose | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD12 | lactitol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD13 | sodium sulfate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD14 | pentaerithrityl | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD15 | macrogol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD16 | mannitol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD17 | sodium phosphate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD18 | sorbitol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD19 | magnesium citrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD21 | sodium tartrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD61 | lactulose, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD65 | macrogol, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG | Enemas | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG01 | sodium phosphate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG02 | bisacodyl | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG03 | dantron, incl. combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG04 | glycerol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG06 | oil | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG07 | sorbitol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG10 | docusate sodium, incl. combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG11 | sodium lauryl sulfoacetate, incl. combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG20 | combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH | Peripheral opioid receptor antagonists | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH01 | methylnaltrexone bromide | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH02 | alvimopan | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH03 | naloxegol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH04 | naloxone | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH05 | naldemedine | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX | Other drugs for constipation | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX01 | glycerol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX02 | carbon dioxide producing drugs | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX03 | lubiprostone | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX04 | linaclotide | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX05 | prucalopride | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX06 | tegaserod | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX07 | plecanatide | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX08 | tenapanor | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX09 | elobixibat | WHO Anatomical Therapeutic Chemical classification
0‑L | A07 | ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A07A | INTESTINAL ANTIINFECTIVES | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA | Antibiotics | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA01 | neomycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA02 | nystatin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA03 | natamycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA04 | streptomycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA05 | polymyxin B | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA06 | paromomycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA07 | amphotericin B | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA08 | kanamycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA09 | vancomycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA10 | colistin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA11 | rifaximin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA12 | fidaxomicin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA13 | rifamycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA51 | neomycin, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA54 | streptomycin, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AB | Sulfonamides | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AB02 | phthalylsulfathiazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AB03 | sulfaguanidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AB04 | succinylsulfathiazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AC | Imidazole derivatives | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AC01 | miconazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX | Other intestinal antiinfectives | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX01 | broxyquinoline | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX02 | acetarsol | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX03 | nifuroxazide | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX04 | nifurzide | WHO Anatomical Therapeutic Chemical classification
0‑L | A07B | INTESTINAL ADSORBENTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BA | Charcoal preparations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BA01 | medicinal charcoal | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BA51 | medicinal charcoal, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BB | Bismuth preparations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC | Other intestinal adsorbents | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC01 | pectin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC02 | kaolin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC03 | crospovidone | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC04 | attapulgite | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC05 | diosmectite | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC30 | combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC54 | attapulgite, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07C | ELECTROLYTES WITH CARBOHYDRATES | WHO Anatomical Therapeutic Chemical classification
0‑L | A07CA | Oral rehydration salt formulations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07D | ANTIPROPULSIVES | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA | Antipropulsives | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA01 | diphenoxylate | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA02 | opium | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA03 | loperamide | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA04 | difenoxin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA05 | loperamide oxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA06 | eluxadoline | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA52 | morphine, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA53 | loperamide, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07E | INTESTINAL ANTIINFLAMMATORY AGENTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA | Corticosteroids acting locally | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA01 | prednisolone | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA02 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA03 | prednisone | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA04 | betamethasone | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA05 | tixocortol | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA06 | budesonide | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA07 | beclometasone | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EB | Antiallergic agents, excl. corticosteroids | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EB01 | cromoglicic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC | Aminosalicylic acid and similar agents | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC01 | sulfasalazine | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC02 | mesalazine | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC03 | olsalazine | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC04 | balsalazide | WHO Anatomical Therapeutic Chemical classification
0‑L | A07F | ANTIDIARRHEAL MICROORGANISMS | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA | Antidiarrheal microorganisms | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA01 | lactic acid producing organisms | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA02 | saccharomyces boulardii | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA03 | escherichia coli | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA51 | lactic acid producing organisms, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07X | OTHER ANTIDIARRHEALS | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA | Other antidiarrheals | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA01 | albumin tannate | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA02 | ceratonia | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA03 | calcium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA04 | racecadotril | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA06 | crofelemer | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA51 | albumin tannate, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A08 | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A08A | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA | Centrally acting antiobesity products | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA01 | phentermine | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA02 | fenfluramine | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA03 | amfepramone | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA04 | dexfenfluramine | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA05 | mazindol | WHO Anatomical Therapeutic Chemical classification
This value set has 6996 codes in it. In order to keep the publication size manageable, only a selection (500 codes) of the whole set of codes is shown.
Legenda: Type L=leaf, S=specializable, A=abstract, D=deprecated. NullFlavor OTH (other) suggests text in originalText. HL7 V3: NullFlavors to appear in @nullFlavor attribute instead of @code.
| XML JSON CSV SQL SVS FHIR (4.0) [xml / json]